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Abstract
Study Objectives: A recent study of patients with moderate–severe obstructive sleep apnea (OSA) in Iceland identified three clinical clusters 
based on symptoms and comorbidities. We sought to verify this finding in a new cohort in Iceland and examine the generalizability of OSA 
clusters in an international ethnically diverse cohort.
Methods: Using data on 972 patients with moderate–severe OSA (apnea–hypopnea index [AHI] ≥ 15 events per hour) recruited from the 
Sleep Apnea Global Interdisciplinary Consortium (SAGIC), we performed a latent class analysis of 18 self-reported symptom variables, 
hypertension, cardiovascular disease, and diabetes.
Results: The original OSA clusters of disturbed sleep, minimally symptomatic, and excessively sleepy replicated among 215 SAGIC patients 
from Iceland. These clusters also generalized to 757 patients from five other countries. The three clusters had similar average AHI values in both 
Iceland and the international samples, suggesting clusters are not driven by OSA severity; differences in age, gender, and body mass index were 
also generally small. Within the international sample, the three original clusters were expanded to five optimal clusters: three were similar to 
those in Iceland (labeled disturbed sleep, minimal symptoms, and upper airway symptoms with sleepiness) and two were new, less symptomatic 
clusters (labeled upper airway symptoms dominant and sleepiness dominant). The five clusters showed differences in demographics and AHI, 
although all were middle-aged (44.6–54.5 years), obese (30.6–35.9 kg/m2), and had severe OSA (42.0–51.4 events per hour) on average.
Conclusions: Results confirm and extend previously identified clinical clusters in OSA. These clusters provide an opportunity for a more 
personalized approach to the management of OSA.
Key words:  obstructive sleep apnea; disease subtypes; personalized medicine; excessive sleepiness; insomnia; minimally symptomatic
Statement of Significance
Obstructive sleep apnea is a heterogeneous disorder—two patients with similar disease severity may experience vastly different symptoms 
and consequences. A prior study in Iceland identified three distinct clinical clusters of patients with obstructive sleep apnea: disturbed 
sleep, minimally symptomatic, and excessively sleepy. Using a clinical sample of patients with moderate–severe sleep apnea recruited 
from across the world as part of the Sleep Apnea Global Interdisciplinary Consortium, this study both replicates the original three clusters 
within a new Icelandic sample and expands on these clusters within a more ethnically diverse population. Establishing the robustness of 
these clinical phenotypes is crucial for future research examining the impact of disease clusters on treatment response and personalized 
obstructive sleep apnea management.
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Introduction
Obstructive sleep apnea (OSA) is a common sleep disorder char-
acterized by repetitive complete or partial closure of the upper 
airway during sleep. An estimated 13% of middle-aged men and 
6% of middle-aged women suffer from moderate–severe disease, 
defined as at least 15 apneas or hypopneas per hour of sleep 
[1]. OSA is associated with a wide range of negative health con-
sequences, including hypertension and cardiovascular disease 
[2–10], diabetes [11, 12], neurodegenerative disorders [13], can-
cer [14], and mortality [15, 16]. Frequently reported symptoms 
in OSA include features of upper airway narrowing (e.g. loud 
snoring, witnessed apneas, and nocturnal gasping), excessive 
sleepiness, sleep disturbances, and general fatigue. It is widely 
recognized that there is considerable variability in etiology, 
symptoms, and consequences of OSA among patients, which 
leads to under-recognition of patients with atypical symptom 
profiles. Thus, recent studies have sought to better characterize 
clinical subtypes of patients with OSA based on demographics, 
disease severity, symptoms, and comorbidities. More accurate 
characterization and diagnosis of OSA is crucial to personalizing 
and improving clinical management.
The first major attempt to identify clinical presentation sub-
types was performed in a population of patients with moderate–
severe OSA from the Icelandic Sleep Apnea Cohort (ISAC) [17]. 
Three distinct clusters were identified as follows: a disturbed 
sleep group characterized by insomnia and restless sleep, a 
minimally symptomatic group, and an excessively sleepy group. 
Subsequent studies in Greece [18], Italy [19], France [20, 21], and 
Europe [22] have suggested additional or different OSA clusters. 
These studies cannot be easily compared because of differences 
in sample characteristics (e.g. inclusion of controls) and vari-
ables used to define clusters (e.g. inclusion of apnea hypopnea 
index [AHI]). However, several studies recognize the existence 
of clusters of patients with relatively low symptom burden, as 
well as clusters with predominant sleep disturbance symptoms 
or daytime sleepiness, as observed in the original ISAC study 
[17]. To further understand individual differences in OSA clini-
cal presentation, in this article, we focus on clinical symptoms 
among patients with moderate–severe disease.
Recent studies suggest that OSA etiology varies between 
racial and ethnic groups [23–27]. For example, Asian patients 
are less obese and have more prevalent craniofacial risk fac-
tors when compared with Caucasians of similar disease sever-
ity [26]. Similarly, OSA has been found to be more severe in 
young African-Americans compared with Caucasians [23]. 
These differences in disease risk factors and etiology may lead 
to distinct symptom profiles and disease consequences among 
ethnicities, raising the question of the robustness and gener-
alizability of OSA clusters previously identified within a single 
ethnic group [28]. Moreover, it is important to know whether 
the findings in Iceland are inherent characteristics of OSA or 
whether they are unique to Iceland, perhaps due to cultural 
norms or referral patterns. This knowledge would advance 
our understanding of OSA and help clinicians better recognize 
the most important disease characteristics in specific patient 
populations.
Towards this end, in the current study, we first sought to 
confirm the presence of the three OSA clinical clusters initially 
identified in ISAC [17] in (1) a new cohort from Iceland and (2) 
an ethnically diverse international cohort. Second, we sought 
to determine the optimal number of clinical clusters that exist 
within the larger ethnically diverse cohort from outside of 
Iceland. We hypothesized that the previously identified OSA 
clusters would be confirmed in Iceland and that similar OSA 
clusters would be observed within the ethnically diverse inter-
national cohort.
Methods
Study participants
An international clinical sample of patients with OSA for the 
present study was recruited from the Sleep Apnea Global 
Interdisciplinary Consortium (SAGIC) study cohort (http://
www.med.upenn.edu/sleepctr/sagic.html). The primary pur-
pose of SAGIC is to establish a large, multinational cohort with 
detailed phenotyping to understand common and ethnicity-
specific OSA presentations and risk profiles. SAGIC consists 
of participants recruited from eight sleep centers in six coun-
tries, including the United States (University of Pennsylvania 
and The Ohio State University), Australia (University of Sydney 
and Sir Charles Gairdner Hospital, Perth), Germany (Charité 
University Hospital), Brazil (Médicado Instituto do Sono), Taiwan 
(Chang Gung Memorial Hospital), and Iceland (Landspitali—The 
National University Hospital of Iceland). Given the goals of the 
present study, participants from Iceland were analyzed sepa-
rately from participants recruited outside of Iceland. Similar to 
the original ISAC study [17], the analysis sample was restricted 
to participants with moderate–severe OSA [defined as AHI ≥ 
15 events per hour] and information available on self-reported 
symptom frequency (Table  1); participants missing responses 
on >5 symptom questions were excluded from analyses. Using 
these criteria, a total of 972 SAGIC participants (215 from Iceland 
and 757 from the remaining sites) were included in analyses. 
The study protocol was approved by the Institutional Review 
Board (IRB) at the University of Pennsylvania and additional IRB 
approval was required and obtained at each site. Informed con-
sent was obtained from all participants.
Sleep studies
In the analysis sample used for clustering (N = 972), a total of 
688 (70.8%) patients were diagnosed using laboratory-based pol-
ysomnography and 284 (29.2%) with home-based sleep studies. 
Standard operating procedures were implemented at each site 
to help ensure uniform data collection. We found a strong inter-
rater agreement of respiratory events in scoring both for in-
laboratory and home studies among the eight sleep centers [29, 
30]. Standards from the American Academy of Sleep Medicine 
(AASM) manual were used to score sleep stages, arousals, and 
respiratory events [31]. Apneas were defined as an absence of 
airflow on the oronasal thermistor or nasal pressure cannula 
for ≥10  s. Hypopneas were defined as a ≥30% reduction from 
baseline in airflow for ≥10 s associated with at least a 4% oxy-
gen desaturation. The AHI was calculated as the mean number 
of apneas and hypopneas per hour of sleep. For home studies, 
total analysis time was assessed based on patient question-
naires regarding sleep onset and wake times and the sleep tech-
nologist’s review of the study; upright time was excluded from 
analysis. This interval was assumed to be sleep duration. In 
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the Icelandic sample, following standard clinical protocol, OSA 
diagnosis was made predominantly using in-home studies, as 
detailed previously [32].
Symptom questionnaire
All SAGIC participants completed a detailed questionnaire on 
demographics, ethnicity, sleep-related symptoms, comorbidi-
ties, and medications. When the SAGIC was started, a common 
questionnaire was developed based on the Basic Nordic Sleep 
Questionnaire (BNSQ) [33], the Berlin Questionnaire [34], the 
Multivariable Apnea Risk Index (MAP) questions on snoring and 
apneas [35], Epworth Sleepiness Scale (ESS) [36], 12-item Short 
Form Health Survey [37], and restless legs syndrome (RLS) symp-
toms [38]. Although the original questionnaires were written in 
English, the SAGIC questionnaire was translated into the lan-
guages of the different participating sites, including Icelandic, 
German, Portuguese, and Mandarin, using forward and back-
ward translation to assure accuracy [39, 40].
The SAGIC questionnaire includes a number of symptom-
related questions, including those related to sleepiness, insom-
nia, nighttime sleep disturbance, abnormal behaviors during 
Table 1. Demographic characteristics of the SAGIC samples
Variable All SAGIC International Iceland P*
N 972 757 215 –
Demographic variables
 Age, years 51.9 ± 12.9 50.9 ± 13.4 55.3 ± 10.4 <0.0001
 Male, % 70.3 72.8 61.4 0.001
 BMI, kg/m2 33.8 ± 8.1 33.8 ± 8.5 34.0 ± 6.5 0.730
 AHI, events/hr 42.9 ± 26.8 46.6 ± 28.4 29.8 ± 13.6 <0.0001
 ODI, events/hr 40.2 ± 27.0 44.0 ± 28.8 27.5 ± 13.4 <0.0001
 Ethnicity, % <0.0001
  Caucasian 58.8 47.5 98.6
  African/African American 5.9 7.6 0.0
  Asian 21.1 27.1 0.0
  Central/South American 6.6 8.5 0.0
  Other 7.6 9.4 1.4
 Site, % <0.0001
  Iceland 22.1 0.0 100.0
  Berlin 7.3 9.4 0.0
  Brazil 10.9 14.0 0.0
  Ohio State 14.5 18.6 0.0
  U Penn 10.4 13.3 0.0
  Sydney 9.0 11.5 0.0
  Perth 6.1 7.8 0.0
  Taiwan 19.8 25.4 0.0
Clustering variables
 Epworth Sleepiness Scale (ESS) 10.2 ± 5.5 10.0 ± 5.6 10.7 ± 4.9 0.067
 Symptom, %
  I feel rested upon waking 18.9 20.4 13.5 0.022
  I feel sleepy during the day 57.1 55.3 63.3 0.038
  Physically tired during the day 80.6 79.3 85.1 0.059
  Fall asleep while watching TV 62.4 59.1 74.0 <0.0001
  Fall asleep involuntarily 26.1 29.3 15.0 <0.0001
  Take naps 77.4 77.9 75.4 0.423
  Frequently doze while driving 8.2 9.5 3.7 0.007
  Difficulty falling asleep 34.7 33.0 40.9 0.031
  Difficulty maintaining sleep 54.1 48.3 74.2 <0.0001
  Waking too early 40.2 39.2 43.5 0.265
  Restless in my sleep 52.2 47.1 70.2 <0.0001
  Wake up with a headache 31.9 31.0 34.9 0.280
  Perspire heavily at night 35.6 33.8 41.9 0.030
  Wake up suddenly, can’t breathe 42.2 42.1 42.5 0.919
  Been told I stop breathing 53.5 51.3 60.9 0.013
  Snoring that disturbs partner 79.3 79.3 79.1 0.932
  Restless Legs Syndrome 13.2 11.3 20.0 0.001
 Hypertension, % 47.2 45.5 52.8 0.060
 Diabetes, % 17.0 17.4 15.8 0.598
 Cardiovascular disease, % 16.0 16.7 13.5 0.253
*p-Value from t test and chi-squared or Fisher’s exact test comparing continuous and categorical variables, respectively, between SAGIC non-Icelandic (international) 
and Iceland samples.
BMI = body mass index; AHI = apnea–hypopnea index; ODI = oxygen desaturation index.
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sleep, upper airway symptoms (snoring, witnessed apneas, and 
waking suddenly unable to breathe), and other symptoms such 
as headaches and excessive sweating. For a majority of included 
symptoms, participants answered using the same format as the 
ISAC, with responses of 0 (never or less than once per month), 
1 (less than once a week), 2 (once or twice a week), 3 (three 
to five times a week), and 4 (every night or almost daily). The 
SAGIC questionnaire also contained a new “don’t know” alter-
native (score 5)  to the questions on symptoms based on the 
BNSQ. For the present analysis, available data on 18 relevant 
OSA symptoms, as well as self-reported diagnoses of medically 
treated hypertension, diabetes, and cardiovascular disease were 
included in the cluster analysis (see Supplementary Table S1 
and Table 1 for additional details on symptom questions, defini-
tions, and frequency).
Statistical analysis
Additional details on the statistical methods can be found in 
Supplementary Material. Continuous variables are summa-
rized with means and standard deviations and compared using 
analysis of variance (ANOVA) or t tests, based on the number of 
groups compared. Categorical variables are summarized using 
frequencies and percentages and compared among clusters 
using chi-squared or Fisher’s exact tests. p-Values of <0.05 were 
considered statistically significant.
Clustering analysis within each sample was performed using 
latent class analysis (LCA), a statistical procedure for grouping 
individuals into a set of mutually exclusive latent classes (i.e. clus-
ters) based on a collection of categorical measurements [41, 42]. 
As in the previous ISAC study [17], participants reporting symp-
toms at least once per week were classified as positive for a given 
symptom; individuals responding “don’t know” were classified as 
negative for the corresponding symptom. Sensitivity analyses per-
formed in the original ISAC clustering analysis showed that OSA 
cluster definitions were robust to this threshold [17].
Given our goal of examining the reproducibility (within 
Iceland) and generalizability (outside of Iceland) of the OSA clus-
ters identified in ISAC [17], we first examined the three-cluster 
solution in both SAGIC samples. In addition to examining the 
results of the three-cluster solution, to determine the optimal 
number of clusters in each sample, we used LCA to obtain solu-
tions for 1 to 10 clusters and compared the resulting Bayesian 
Information Criterion (BIC) values. Lower BIC values indicate 
better model fit; thus, the “optimal clustering solution” was 
defined as the number of clusters that resulted in the lowest 
BIC. Symptom and demographic characteristics were sum-
marized and compared across the clusters using ANOVA and 
chi-squared or Fisher’s exact tests. The symptoms and clinical 
interpretations, as well as the prevalences of the three-cluster 
solutions, were qualitatively compared with the original defini-
tions described in ISAC [17].
Results
Sample characteristics
A total of 972 SAGIC patients recruited from international sleep 
clinics with an AHI ≥ 15 events per hour and available symptom 
questionnaire data were included in clustering analyses (Table 1). 
Participants were on average middle-aged (51.9  ±  12.9  years), 
predominantly male (70.3%), moderately obese (33.8  ±  8.1  kg/
m2), and had severe OSA based on AHI (42.9 ± 26.8 events per 
hour). SAGIC is an ethnically diverse population, with 58.8% 
Caucasian, 21.1% Asian, 5.9% African/African American, 6.6% 
Central/South American, and 7.6% reporting other or multiple 
racial/ethnic groups.
Table  1 also compares the Icelandic (N  =  215) and non-Ice-
landic (N = 757) SAGIC samples. Patients recruited from Iceland 
were generally older, less likely to be male and had less severe 
OSA than the non-Icelandic patients. There were differences in 
a number of clinical symptoms in the sample from Iceland com-
pared with the SAGIC sample from outside of Iceland, including 
higher prevalences of disturbed sleep, RLS, and symptoms related 
to sleepiness or dozing. There were no significant differences in 
the prevalence of hypertension (p = 0.060), diabetes (p = 0.598), or 
cardiovascular disease (p = 0.253) between the two samples.
Validation of the three-symptom clusters in samples 
from Iceland
We first sought to replicate the ISAC clusters within the subset 
of the SAGIC sample from Iceland. When examining up to 10 
clusters, the optimal result (based on BIC, see Supplementary 
Table S2) was the three-cluster solution, replicating the original 
finding in ISAC [17]. Moreover, both the clinical interpretations 
and prevalence of the three clusters were similar between the 
SAGIC samples from Iceland and ISAC, providing independent 
validation of the OSA clinical clusters in Iceland (Table 2).
Similar OSA symptom clusters within the independent SAGIC 
sample from Iceland.
The symptom characteristics of the three-cluster definitions 
in SAGIC participants from Iceland were similar to those in the 
original ISAC study (Table 2 and Figure 1), namely, the disturbed 
sleep, minimally symptomatic, and excessively sleepy.
Cluster 1 (N  =  72 [33.5%]) is similar to the ISAC disturbed 
sleep cluster, with the highest rates of difficulty falling asleep 
(70.8%), difficulty maintaining sleep (95.8%), waking too early 
(61.1%), and restless sleep (91.7%). This cluster had relatively 
low rates of reported daytime sleepiness. Rates of upper airway 
symptoms (snoring, witnessed apneas, and waking suddenly 
unable to breathe) in this cluster were more similar to those in 
the minimally symptomatic cluster, described below.
Cluster 2 (N  =  62 [28.8%]) is similar to the ISAC minimally 
symptomatic cluster. This cluster had the lowest symptom bur-
den and the highest prevalence of feeling rested upon waking. In 
contrast to the results in ISAC, the prevalence of comorbidities 
was not significantly higher in this cluster within the Iceland 
SAGIC participants (Table 2).
Finally, Cluster 3 (N = 81 [37.7%]) is similar to the ISAC exces-
sively sleepy cluster. This cluster had an average ESS of 15.3 
and high prevalence of feeling sleepy, dozing, and napping. This 
group also contained all participants who reported dozing while 
driving (9.9%). The excessively sleepy cluster also had the high-
est rates of upper airway symptoms.
Comparable symptom cluster prevalence in the two samples 
from Iceland.
In addition to comparable symptoms, the three clusters had 
similar prevalence in ISAC and the SAGIC participants from 
Iceland (p = 0.340 for overall comparison). In both samples, the 
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excessively sleepy cluster was the most prevalent (42.6% in ISAC 
and 37.7% in SAGIC; p = 0.194), followed by the disturbed sleep 
cluster (32.7% and 33.5%, p = 0.832), and the minimally symp-
tomatic group the least prevalent (24.7% and 28.8%, p = 0.215).
Demographic characteristics of the three symptom clusters.
There were some differences in demographic factors between 
the three clusters (Table  2), which could suggest distinct OSA 
manifestations in certain demographic subgroups. Specifically, 
there was a significant difference in gender (p = 0.0003) and a bor-
derline association with age (p = 0.057) across the clusters. The 
disturbed sleep cluster had the highest proportion of females, 
whereas the minimally symptomatic cluster was 3–4 years older 
than the other clusters. We observed no significant differences 
in body mass index (BMI) or OSA severity among clusters. These 
demographic associations were similar to those noted in the 
original ISAC study [17], including an older age in the minimally 
symptomatic and no differences in BMI or OSA severity.
Generalization of the three-symptom clusters in the 
international sample
Next, we examined the results of a three-cluster solution in 
the more ethnically diverse SAGIC population from outside of 
Iceland (Table 3 and Figure 1). Within this multinational sample, 
the three OSA clusters showed similar clinical symptom defini-
tions as those originally defined in ISAC [17]; however, there was 
a difference in the prevalence of the clusters. In addition, there 
are clear similarities in the symptom burdens of the three clus-
ters generated from the SAGIC Iceland sample and this interna-
tional SAGIC sample (Figure 1).
Symptoms of the three clusters from ISAC generalize to 
international SAGIC population.
We found that the three clusters defined in the ISAC sample, i.e. 
disturbed sleep, minimally symptomatic, and excessively sleepy, 
were present in the international population of SAGIC partici-
pants from outside of Iceland (Table 3 and Figure 1).
Cluster 1 (N  =  150 [19.8%]) is similar to the ISAC disturbed 
sleep cluster, with the highest rates of difficulty falling asleep 
(80.7%), difficulty maintaining sleep (91.9%), waking too early 
(75.8%), and restless sleep (78.0%), and only modest levels of 
daytime sleepiness. However, in contrast to the ISAC findings 
[17], this disturbed sleep cluster also had the highest rates of 
hypertension, diabetes, and cardiovascular disease.
Cluster 2 (N = 306 [40.4%]) had the lowest proportion of sleep-
iness-related complaints (average ESS of 6.3), the highest pro-
portion of patients reporting feeling rested upon waking, and 
Table 2. Symptom summary for three-cluster solution in the SAGIC Iceland sample
Variable Cluster 1 Cluster 2 Cluster 3 P*
Name Disturbed sleep Minimally symptomatic Excessively sleepy
N (%) 72 (33.5%) 62 (28.8%) 81 (37.7%) –
Clustering variables
 Epworth Sleepiness Scale (ESS) 8.2 ± 3.3 7.7 ± 3.7 15.3 ± 3.2 <0.0001
 Symptom, %
  I feel rested upon waking 2.8 41.9 1.2 <0.0001
  I feel sleepy during the day 63.9 21.0 95.1 <0.0001
  Physically tired during the day 100.0 53.2 96.3 <0.0001
  Fall asleep while watching TV 56.9 62.9 97.5 <0.0001
  Fall asleep involuntarily 2.8 0.0 37.0 <0.0001
  Take naps 69.4 66.1 87.7 0.005
  Frequently doze while driving 0.0 0.0 9.9 0.001
  Difficulty falling asleep 70.8 19.4 30.9 <0.0001
  Difficulty maintaining sleep 95.8 41.7 79.0 <0.0001
  Waking too early 61.1 27.9 39.5 0.0004
  Restless in my sleep 91.7 41.9 72.8 <0.0001
  Wake up with a headache 56.9 8.1 35.8 <0.0001
  Perspire heavily at night 56.9 16.1 48.1 <0.0001
  Wake up suddenly and can’t breathe 26.4 24.6 70.4 <0.0001
  Been told I stop breathing 45.8 51.6 81.5 <0.0001
Snoring 0.001
   No snoring 5.6 11.3 6.2
   Snoring that does not disturb partner 16.7 24.2 2.5
   Snoring that disturbs partner 77.8 64.5 91.4
  Restless legs syndrome 23.6 14.5 21.0 0.406
 Hypertension 59.7 54.8 45.0 0.179
 Diabetes 11.1 21.0 16.0 0.296
 Cardiovascular disease 8.3 12.9 18.5 0.181
Demographic variables
 Age, years 54.6 ± 10.3 57.9 ± 9.4 53.8 ± 10.9 0.057
 Male, % 43.1 66.1 74.1 0.0003
 BMI, kg/m2 33.5 ± 5.9 33.9 ± 5.6 34.5 ± 7.5 0.609
 AHI, events/hr 27.2 ± 10.8 30.2 ± 13.9 31.9 ± 15.3 0.094
 ODI, events/hr 25.4 ± 11.1 27.3 ± 13.8 29.6 ± 14.8 0.148
*p-Value from analysis of variance and chi-squared or Fisher’s exact tests comparing continuous and categorical variables, respectively, across clusters.
BMI = body mass index; AHI = apnea–hypopnea index; ODI = oxygen desaturation index.
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the lowest prevalence of insomnia-related symptoms. Thus, 
this cluster is similar to the ISAC minimally symptomatic. As 
in the SAGIC sample from Iceland, but in contrast to the results 
in ISAC, this cluster did not have higher rates of comorbidities.
Finally, Cluster 3 (N = 301 [39.8%]) is similar to the ISAC exces-
sively sleepy cluster, with an average ESS of 15.0 and the highest 
rates of feeling sleepy and dozing. As in ISAC, this cluster also 
had the highest rates of upper airway symptoms (e.g. snoring, 
witnessed apneas, and waking suddenly unable to breathe).
Differences in cluster prevalence between ISAC and ethnically 
diverse SAGIC sample.
Although the three-cluster solution generalizes to the SAGIC 
sample from outside of Iceland, there were differences in clus-
ter prevalence (p  <  0.0001); this may reflect ethnic differences 
in symptom occurrence or reporting. Compared with ISAC, the 
SAGIC sample from outside of Iceland had similar prevalence 
of the excessively sleepy cluster (39.8% vs. 42.6%; p  =  0.256), 
lower prevalence of the disturbed sleep cluster (19.8% vs. 32.7%; 
p  <  0.0001), and higher prevalence of the minimally sympto-
matic cluster (40.4% vs. 24.7%; p < 0.0001).
Demographic characteristics of the three clusters in SAGIC 
participants from outside of Iceland.
When examining demographics and OSA severity across 
the three clusters (Table  3), there were no differences in AHI 
(p = 0.298) or oxygen desaturation index (ODI; p = 0.393), as in the 
original ISAC analysis [17]; all clusters had severe OSA on aver-
age. Significant differences among the clusters were observed 
in age, gender, BMI, and ethnicity; these demographics could 
Figure 1. Profiles of the three OSA clusters in Icelandic and International SAGIC samples. The relative differences in symptoms among the three OSA clusters (disturbed 
sleep, minimally symptomatic, and excessively sleepy) are shown in heatmaps within the Icelandic and International samples, separately, where blue indicates a lower 
relative prevalence/burden and red a higher relative symptom burden. The heatmaps illustrate both the higher prevalence of reported sleepiness and upper airway 
symptoms in the excessively sleepy and the higher rates of restless sleep and insomnia symptoms in the disturbed sleep. We also see the relative lower reported 
symptom burden in the minimally symptomatic cluster. Importantly, note the clear similarities in symptom profiles between the Icelandic and International samples 
of patients. This strongly supports the notion that these OSA subtypes are reproducible both inside and outside of Iceland.
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be valuable when evaluating an individual patient with OSA. 
Whereas in Iceland the minimally symptomatic group was the 
oldest on average [17], in this international sample the disturbed 
sleep cluster was the oldest (54.0  years) and the excessively 
sleepy the youngest (49.1  years). The minimally symptomatic 
cluster showed the highest proportion of males (80.4%) and 
the lowest BMI (32.2  kg/m2), as well as the lowest proportion 
of Caucasian (41.1%) and highest percentage of Asian (34.9%) 
participants.
Optimal symptom cluster solution in the 
international sample
Based on statistical criteria (lowest BIC value), the optimal cluster-
ing solution for the international SAGIC sample was five clusters 
rather than three (Supplementary Table S3). Reasonable clinical 
interpretations were derived for all five clusters, as discussed 
below (Table 4 and Figure 2). Moreover, relationships between this 
optimal five-cluster solution and the three-cluster solution help us 
to understand clinical significance (Figure 3 and Supplementary 
Figure S1). Ultimately, the five-cluster solution may provide addi-
tional clinical insights into major complaints for a given patient 
and, relatedly, the primary reasons for sleep center referral.
The five-cluster solution identifies additional subgroups 
characterized by primary symptom complaints.
In the five-cluster solution, three clusters were similar to the 
disturbed sleep, minimally symptomatic, and excessively sleepy 
clusters previously described; greater than eighty percent of 
individuals in these optimal clusters came from the similar 
cluster in the three-cluster design (Figure 3). The two new clus-
ters were defined by predominance of upper airway symptoms 
(Cluster 4) or sleepiness (Cluster 5), with few other symptoms. 
These two clusters included a mixture of patients from each 
Table 3. Symptom summary for three-cluster solution in the international SAGIC sample
Variable Cluster 1 Cluster 2 Cluster 3 P*
Name Disturbed sleep Minimally symptomatic Excessively sleepy
N (%) 150 (19.8) 306 (40.4) 301 (39.8) –
Clustering variables
 Epworth Sleepiness Scale 7.4 ± 3.6 6.3 ± 3.8 15.0 ± 4.0 <0.0001
 Symptom, %
  I feel rested upon waking 7.3 45.1 2.0 <0.0001
  I feel sleepy during the day 55.7 21.8 89.0 <0.0001
  Physically tired during the day 88.0 56.9 97.7 <0.0001
  Fall asleep while watching TV 38.0 35.1 94.0 <0.0001
  Fall asleep involuntarily 10.1 2.6 66.1 <0.0001
  Take naps 75.7 67.9 89.3 <0.0001
  Frequently doze while driving 2.7 3.9 18.6 <0.0001
  Difficulty falling asleep 80.7 10.5 32.0 <0.0001
  Difficulty maintaining sleep 91.9 15.2 60.2 <0.0001
  Waking too early 75.8 14.9 45.6 <0.0001
  Restless in my sleep 78.0 18.4 60.9 <0.0001
  Wake up with a headache 38.0 12.8 46.0 <0.0001
  Perspire heavily at night 44.0 16.4 46.3 <0.0001
  Wake up suddenly and can’t breathe 31.3 29.8 60.1 <0.0001
  Been told I stop breathing 34.7 41.4 69.7 <0.0001
  Snoring <0.0001
   No snoring 18.0 18.8 2.0
   Snoring that does not disturb partner 11.3 7.2 9.0
   Snoring that disturbs partner 70.7 74.0 89.0
  Restless legs syndrome 21.4 2.4 15.0 <0.0001
 Hypertension 61.4 41.3 41.7 <0.0001
 Diabetes 26.0 15.4 15.0 0.008
 Cardiovascular disease 25.2 15.0 14.3 0.009
Demographic variables
 Age, years 54.0 ± 12.6 51.2 ± 14.2 49.1 ± 12.5 0.001
 Male, % 63.3 80.4 69.8 0.0002
 BMI, kg/m2 35.5 ± 8.8 32.2 ± 7.9 34.5 ± 8.7 0.0001
 AHI, events/hr 46.4 ± 29.6 44.8 ± 24.9 48.4 ± 31.0 0.298
 ODI, events/hr 43.2 ± 29.5 42.7 ± 26.2 45.8 ± 30.8 0.393
 Ethnicity, % 0.0009
  Caucasian 58.4 41.1 48.5
  African/African American 10.1 5.9 8.0
  Asian 16.8 34.9 24.3
  Central/South American 4.7 9.9 9.0
  Other 10.1 8.2 10.3
*p-Value from analysis of variance or chi-squared tests comparing continuous and categorical variables, respectively, across clusters.
BMI = body mass index; AHI = apnea–hypopnea index; ODI = oxygen desaturation index.
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of the original three clusters, although the majority came from 
the minimally symptomatic and excessively sleepy clusters 
(Figure 3 and Supplementary Figure S1).
Specifically, Cluster 1 (N = 144 [19.0%]) is characterized pri-
marily by disturbed sleep symptoms, and 80.6% of this cluster 
was from the similar disturbed sleep cluster in the three-cluster 
solution (Figure  3). A  large majority of patients in this cluster 
reported insomnia-related symptoms, including 82.4% difficulty 
falling asleep, 97.2% difficulty maintaining sleep, 77.3% waking 
too early, and 79.7% reporting restless sleep. This cluster also 
had the highest rates of hypertension, diabetes, and cardiovas-
cular disease.
Cluster 2 (N = 154 [20.3%]) consists of patients with OSA with 
minimal symptoms, and 95.5% of this subgroup fell within the 
minimally symptomatic cluster in the three-cluster solution 
(Figure  3). Despite having moderate–severe OSA, most symp-
toms included in our clustering algorithm were reported by less 
than 25% of the individuals in this minimal symptoms cluster. 
These patients had the lowest average ESS (4.7  ±  2.7), 75.2% 
reported feeling rested upon waking, and 26.1% reported no 
snoring. Overall, patients in this cluster appear resilient to usual 
clinical features of OSA, and thus, the impact of disease may not 
be reflected in measured symptoms.
Cluster 3 (N = 164 [21.7%]) represents the classic presentation 
of OSA, i.e. upper airway symptoms with sleepiness. All mem-
bers of this cluster were part of the excessively sleepy cluster 
in the three-cluster solution (Figure  3), suggesting that it rep-
resents a more well-defined subset of the cluster identified in 
ISAC. Individuals in this cluster had the most severe sleepiness, 
with an average ESS of 16.3 and 28.0% reporting frequent doz-
ing when driving, as well as the second highest rates of sleep 
disturbance (e.g. restless sleep and difficulty maintaining sleep). 
This cluster also reported high rates of upper airway symptoms 
(e.g. snoring, witnessed apneas, and waking suddenly unable to 
breathe).
Cluster 4 (N  =  147 [19.4%]) includes patients whose symp-
toms are dominated by indications of upper airway obstruction 
and thus is characterized as upper airway symptoms dominant 
OSA. As shown in Figure 3, a majority of this cluster (59.9%) was 
classified as minimally symptomatic in the three-cluster solu-
tion, whereas 27.2% were in the excessively sleepy and 12.9% in 
the disturbed sleep clusters. This cluster had high rates of snor-
ing, witnessed apneas, and waking suddenly unable to breathe, 
despite comparatively low rates of sleepiness or insomnia-
related symptoms. Also, this cluster has the lowest prevalence 
of hypertension, diabetes, and cardiovascular disease of all the 
five clusters. Thus, individuals in this cluster are most likely to 
have been referred to sleep clinics due to recognized upper air-
way symptoms of OSA.
Finally, Cluster 5 (N = 148 [19.6%]) includes individuals with 
excessive sleepiness, but a relative absence of symptoms of upper 
airway obstruction; thus, this cluster is labeled as sleepiness 
Table 4. Symptom summary for optimal clusters in the international SAGIC sample
Variable Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 P*
Name Disturbed sleep
Minimal 
symptoms
Upper airway 
symptoms with 
sleepiness
Upper airway 
symptoms 
dominant
Sleepiness 
dominant –
N (%) 144 (19.0) 154 (20.3) 164 (21.7) 147 (19.4) 148 (19.6) –
Epworth Sleepiness Scale 8.4 ± 3.9 4.7 ± 2.7 16.3 ± 3.7 8.1 ± 4.5 12.1 ± 4.4 <0.0001
Symptom, %
 I feel rested upon waking 0.7 75.2 1.2 10.3 14.2 <0.0001
 I feel sleepy during the day 60.1 5.3 96.3 34.0 77.7 <0.0001
 Physically tired during the day 93.1 24.8 100.0 95.2 83.7 <0.0001
 Fall asleep while watching TV 49.7 21.4 98.2 44.9 78.2 <0.0001
 Fall asleep involuntarily 17.5 0.0 85.2 4.1 35.7 <0.0001
 Take naps 79.6 62.7 94.4 66.4 85.6 <0.0001
 Frequently doze while driving 2.2 0.0 28.0 14.3 1.4 <0.0001
 Difficulty falling asleep 82.4 18.2 43.9 12.9 8.8 <0.0001
 Difficulty maintaining sleep 97.2 22.4 75.6 25.9 20.4 <0.0001
 Waking too early 77.3 22.5 57.1 23.8 15.6 <0.0001
 Restless in my sleep 79.7 20.8 71.8 29.9 32.7 <0.0001
 Wake up with a headache 43.1 3.9 56.4 22.4 27.9 <0.0001
 Perspire heavily at night 49.3 12.4 56.4 26.5 23.1 <0.0001
 Wake up suddenly and can’t 
breathe
26.6 16.4 77.9 78.1 8.2 <0.0001
 Been told I stop breathing 27.3 24.3 88.4 95.2 17.6 <0.0001
 Snoring <0.0001
  No snoring 14.6 26.1 0.6 0.0 19.1
  Snoring that does not disturb 
partner
16.0 7.2 8.5 3.4 8.8
  Snoring that disturbs partner 69.4 66.7 90.9 96.6 72.1
 Restless legs syndrome 24.8 2.0 16.4 4.9 8.4 <0.0001
Hypertension 63.1 51.7 44.8 16.4 51.1 <0.0001
Diabetes 27.0 16.9 15.8 2.8 24.3 <0.0001
Cardiovascular disease 23.9 18.1 15.2 7.0 19.4 0.003
*p-Value from analysis of variance or chi-squared tests comparing continuous or categorical variables, respectively, across clusters.
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dominant OSA. This cluster was a mix of patients from the min-
imally symptomatic (46.6%) and excessively sleepy (48.0%) clus-
ters in the three-cluster solution (Figure 3). Individuals in this 
cluster met clinical thresholds for subjective sleepiness (mean 
ESS of 12.1) and had the second highest rates of daytime sleepi-
ness, dozing, and taking naps. Given these symptoms, combined 
with lower rates of symptoms of upper airway obstruction, this 
cluster of patients may have been referred to the clinic due to 
unexplained daytime sleepiness.
Demographic characteristics of the five clusters in SAGIC 
participants from outside of Iceland.
We observed statistically significant differences in age, gender, 
BMI, and ethnicity among the five clusters (Table 5). There were 
also differences in OSA severity, although all clusters had severe 
disease on average. The upper airway symptoms dominant clus-
ter was the youngest (44.6 years), least obese (30.6 kg/m2), and 
had the highest proportion of both males (89.1%) and partici-
pants of Asian ethnicity (43.8%). In contrast, the disturbed sleep 
Figure 2. Profiles of the five optimal OSA clusters in the International SAGIC sample. The relative symptom burden is shown in a heatmap for each of the five optimal 
clusters (disturbed sleep, minimal symptoms, upper airway symptoms with sleepiness, upper airway symptoms dominant, and sleepiness dominant), ranging from 
low burden (blue) to high burden (red). In addition to illustrating the symptomatic differences among the five clusters, note the similarities between the heatmaps 
for the disturbed sleep, minimal symptoms, and upper airway symptoms with sleepiness and the corresponding heatmaps for the three-cluster solutions in Figure 1.
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cluster was the oldest (54.5 years), the most obese (35.9 kg/m2), 
and had the highest proportions of females (43.1%), Caucasians 
(59.4%), and African/African Americans (12.6%) compared with 
the other clusters. Overall, the prevalence of the upper airway 
symptoms dominant (p < 0.0001) and disturbed sleep (p < 0.0001) 
clusters differed significantly across ethnicities, whereas prev-
alences of the other three clusters were similar across ethnic 
groups (Supplementary Table S4). The clusters of upper airway 
symptoms dominant and upper airway symptoms with sleepi-
ness had the most severe OSA, with AHI and ODI values 5–10 
events per hour higher than the other three clusters. Overall, 
differences in these characteristics may reflect distinct manifes-
tations of OSA based on clinically observed traits such as gender, 
obesity, and ethnicity.
Discussion
This study represents an essential next step in understand-
ing OSA clinical presentation clusters, building on those origi-
nally described in the ISAC [17]. Using an international sample 
of apneics recruited from sleep clinics in the SAGIC, we dem-
onstrate the reproducibility of the disturbed sleep, minimally 
symptomatic, and excessively sleepy OSA clusters within an 
independent sample from Iceland and in a more ethnically 
diverse sample from outside of Iceland. Although the three 
clinical subtypes were generalizable, our results suggested more 
specific OSA clinical clusters within the international SAGIC 
sample, furthering our understanding of OSA heterogeneity. 
Specifically, the optimal solution resulted in five OSA clusters, 
three of which were similar to the disturbed sleep, minimally 
symptomatic, and excessively sleepy clusters defined in ISAC—
labeled here as disturbed sleep, minimal symptoms, and upper 
airway symptoms with sleepiness—and two new subtypes asso-
ciated with a paucity of other symptoms—labeled as upper air-
way symptoms dominant and sleepiness dominant. Overall, this 
study provides a novel approach to better characterize patients 
with OSA presenting at sleep clinics worldwide. This informa-
tion can help inform personalized medicine approaches to OSA 
treatment by allowing clinicians to focus interventions on the 
most relevant OSA symptoms and consequences within an indi-
vidual patient.
The observation that the clinical clusters defined in ISAC 
[17] both replicate with respect to symptom characteristics and 
prevalence in an independent Icelandic sample and general-
ize to other ethnicities provides strong evidence that these are 
true disease clusters among patients with OSA. Although five 
OSA clusters proved to be the optimal number from a statisti-
cal perspective in the SAGIC samples from outside of Iceland, 
we noted clear similarities with the three-cluster solution from 
ISAC. Both solutions identified individuals with disturbed sleep, 
a lack of traditional symptoms, and the classical OSA presen-
tation of excessive sleepiness and upper airway symptoms; a 
large proportion of patients remained similarly defined in both 
the three- and five-cluster solutions. Thus, utilizing three or 
five clusters may provide similar benefits in clinical practice. 
Figure  3. Distribution of the a priori three–OSA clusters within the five opti-
mal OSA clusters found in the International SAGIC sample. The proportions of 
patients from the a priori three–cluster solution within each of the optimal five 
clusters are shown. We note that >80% of the disturbed sleep, minimal symp-
toms, and upper airway symptoms with sleepiness clusters are made up of 
patients from the similar group in the three-cluster solution, whereas the new 
upper airway symptoms dominant and sleepiness dominant clusters consist 
primarily of a mixture of patients from the minimally symptomatic and exces-
sively sleepy clusters.
Table 5. Demographic characteristics of optimal clusters in the international SAGIC sample
Variable Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 P*
Name Disturbed sleep
Minimal 
symptoms
Upper airway 
symptoms with 
sleepiness
Upper airway 
symptoms 
dominant
Sleepiness 
dominant –
N (%) 144 (19.0) 154 (20.3) 164 (21.7) 147 (19.4) 148 (19.6) –
Age, years 54.5 ± 12.7 54.2 ± 13.9 49.5 ± 12.0 44.6 ± 12.1 51.9 ± 13.6 <0.0001
Male, % 56.9 78.6 70.7 89.1 68.2 <0.0001
BMI, kg/m2 35.9 ± 8.3 33.3 ± 8.9 35.1 ± 8.9 30.6 ± 6.3 34.0 ± 8.7 <0.0001
AHI, events/hr 44.7 ± 30.8 43.5 ± 24.6 51.4 ± 31.4 50.6 ± 26.0 42.0 ± 27.4 0.007
ODI, events/hr 40.6 ± 30.9 40.1 ± 25.7 48.1 ± 30.3 50.5 ± 27.3 40.1 ± 27.9 0.001
Ethnicity, % <0.0001
 Caucasian 59.4 48.4 51.8 35.6 41.9
 African/African American 12.6 5.2 7.9 2.7 9.5
 Asian 13.3 25.5 22.6 43.8 30.4
 Central/South American 5.6 8.5 7.9 11.0 9.5
 Other 9.1 12.4 9.8 6.9 8.8
*p-Value from analysis of variance (continuous) and chi-squared test (categorical) comparing values across clusters.
BMI = body mass index; AHI = apnea–hypopnea index; ODI = oxygen desaturation index.
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The added clinical benefit of the five OSA clusters appears to 
be improved accuracy with respect to primary symptom com-
plaints; the new clusters of upper airway symptoms dominant 
and sleepiness dominant included patients with a narrower 
symptom spectrum. The ability to more quickly identify these 
main symptoms could improve efficiency in both diagnosis and 
treatment decisions.
Comparisons to phenotypes suggested by prior OSA 
clustering studies
Following the initial clustering in ISAC [17], other publications 
have examined OSA clusters [18–21]. For example, a study in 
Greek patients (N = 1472) utilized a combination of the Charlson 
Comorbidity Index and OSA severity to identify six clusters 
ranging from healthy participants with sleep-related distur-
bances and moderate somnolence to severe OSA with severe 
comorbidities, sleepiness, and obesity [18]. Another study of 198 
patients with OSA from southern Italy identified three clusters 
driven by age, obesity, and OSA/hypoxemia severity [19]. Finally, 
a large study examining symptoms, demographics, disease 
severity, comorbidities, and environmental risk factors in 18,263 
moderate–severe apneics from France [20] yielded six clusters, 
labeled as follows: (1) young symptomatic, (2) older obese, (3) 
multidisease old obese, (4) young snorers, (5) drowsy obese, and 
(6) multidisease obese symptomatic. Although each study falls 
under the umbrella of OSA phenotyping, there are predictable 
distinctions related to the differences in underlying populations 
and the variables used to determine clusters. However, there 
are also similarities among studies. Of particular note are paral-
lels between results found in the present article and the large 
clustering study in France [20]. The young snorers show demo-
graphic parallels to SAGIC individuals labeled as upper airway 
symptoms dominant; both clusters were younger, less obese, 
and had the highest proportion of males. Similarly, the SAGIC 
cluster of sleepiness dominant parallels the drowsy obese in 
France, and the minimal symptoms cluster, which was the old-
est and moderately obese, is similar to the older obese. Finally, 
the multidisease old obese and multidisease obese symptomatic 
defined in France are similar to the SAGIC clusters of disturbed 
sleep and upper airway symptoms with sleepiness. Although 
these similarities support reproducible underlying OSA clusters, 
the absence of information on insomnia-related symptoms in 
the French study highlights the impact of methodological differ-
ences. Given our results and other research [43], this prior study 
may have missed an important distinguishing characteristic 
among patients with OSA, namely, comorbid insomnia.
Our choice to focus on clinical symptoms within moder-
ate–severe patients with OSA reflects the goal of moving beyond 
typical severity and demographic metrics used to characterize 
OSA and towards an understanding of individual differences in 
clinical presentation. In contrast, including disease severity as a 
clustering input variable, as well as mild OSA and control par-
ticipants in study populations, has resulted in disease clusters 
that differ primarily by existing OSA severity metrics. Similarly, 
studies utilizing demographic variables (e.g. age and BMI) to 
determine clusters have found subtypes defined by differences 
in these usual metrics, rather than leveraging these measures to 
help understand the etiology of independently defined clusters. 
Ultimately, the limited difference in OSA severity between our 
clusters underscores an important clinical reality—two patients 
with the same physiological disease severity may present with 
distinct clinical symptoms.
Implications of differences in cluster prevalence 
based on demographic factors
Another important aspect of the current analysis is the ethnic 
diversity available in SAGIC. For the three OSA clusters origi-
nally described in ISAC, nearly half of Asian and Central/South 
American patients displayed the minimally symptomatic sub-
type; these patients were less likely to display the disturbed 
sleep cluster. Conversely, the distributions of the three clusters 
among Caucasians and African/African Americans were gen-
erally similar. For the optimal five OSA clusters, nearly one-
third of Asian patients fell into the upper airway symptoms 
dominant group. This cluster was least prevalent in African/
African-American individuals, who were most likely to fall into 
the disturbed sleep cluster. Caucasian participants showed a 
relatively equal distribution across the five clusters, whereas 
Central/South Americans were least likely to display the dis-
turbed sleep cluster, but showed similar prevalence across the 
other four clusters. These differences in cluster prevalence 
across ethnicities may reflect cultural or regional differences in 
symptom reporting [44, 45] or referral strategies and access to 
care, as well as previously identified differences in OSA etiology 
across ethnic groups [23–27].
Differences in age, gender, or obesity may provide similar 
insight into distinct disease etiologies or consequences, helping 
us to predict the most likely clinical presentations of OSA within 
a given patient. For example, we noted a consistent ordering of 
clusters with respect to mean age and prevalence of comorbidi-
ties. The upper airway symptoms dominant cluster showed the 
youngest age and least prevalence of comorbidities, followed by 
the upper airway symptoms with sleepiness cluster, the sleepi-
ness dominant or minimal symptoms clusters, and the disturbed 
sleep cluster showing the oldest age and highest prevalence of 
comorbidities. Although only speculative, one explanation for 
this ordering is that the symptom profile changes with dura-
tion of undiagnosed disease (reflected imprecisely by age in our 
cohort), and the longer you have the disease, the more likely you 
are to develop an OSA-related comorbidity. Ultimately, recogniz-
ing clinical factors affecting the prevalence of specific clusters is 
important for both diagnosis and personalized disease manage-
ment within a given individual or ethnic population.
Next steps for clusters in OSA: insights from other 
diseases
There is increasing awareness of the importance of character-
izing distinct disease clusters within heterogeneous, complex 
disorders such as OSA. Findings from phenotyping studies in 
asthma [46] and COPD [47, 48], for example, offer helpful insights 
for the future of OSA clusters. In COPD [47, 48], clustering anal-
ysis has led to characterization of disease severity based not 
only on airflow limitation (forced expiratory volume in 1 second 
[FEV1]), but also on symptoms and risk of future exacerbations; 
this approach is being further extended to include treatable bio-
logical and clinical factors for optimizing personalized medicine 
approaches [47, 48]. A primary impetus for this change was the 
recognition that, while important, FEV1 is only weakly associ-
ated with symptoms and risk of future events [47, 48]. Similar 
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observations have been made for the OSA clusters described 
here, which do not differ dramatically by the primary meas-
ure of disease severity—the AHI. This underscores the need to 
move beyond a single measure of OSA severity to characterize 
heterogeneity.
Relatedly, asthma [46] was initially defined as a single 
umbrella phenotype encompassing a wide degree of hetero-
geneous patient symptoms, severity, onset age, and inflam-
matory characteristics (including the role of T helper [TH2] 
immune elements). Recognizing this, studies have suggested 
different asthma phenotypes, including TH2-associated (e.g. 
early-onset  allergic, late-onset persistent eosinophilic, and 
exercise-induced asthma) and non-TH2-associated (e.g., obesity-
related and neutrophilic asthma) [46]. Importantly, these asthma 
phenotypes have implications for personalized treatments. For 
example, TH2-targeted therapies such as corticosteroids are 
likely to be most effective in TH2-associated asthma, whereas 
weight loss may be more effective in non-TH2, obesity-related 
asthma. Developing personalized treatment strategies is crucial 
for applying precision medicine techniques to OSA clinical care.
Implications of clusters on determining OSA 
treatment response
Understanding the implication of clinical clusters on treatment 
approaches, particularly for individuals or symptoms that do 
not respond to positive airway pressure (PAP), is an important 
next step. Recent studies have combined OSA phenotyping with 
assessment of treatment adherence and efficacy [21, 22], includ-
ing a companion article, Changing Faces of OSA: Treatment Effects 
by Cluster Designation in the Icelandic Sleep Apnea Cohort [49].
In particular, this companion article utilizes follow-up 
data on the ISAC sample to examine differences in symptom 
responses after 2  years of PAP treatment among the clinical 
clusters defined at baseline [49]. In addition to a small increase 
in overall PAP adherence in the excessively sleepy cluster, there 
was evidence for differential OSA treatment response pat-
terns related to initial OSA cluster. The excessively sleepy clus-
ter showed a wide range of symptom improvements, whereas 
insomnia symptoms were more resistant to PAP therapy in the 
disturbed sleep group. Importantly, all three clusters, includ-
ing the minimally symptomatic group, showed some benefit of 
treatment. Thus, results highlight the importance of considering 
initial clinical presentation to more accurately define treatment 
response within a given patient and not relying solely on typical 
OSA symptoms when recommending therapy.
Relatedly, Gagnadoux et al. utilized demographic, symptom, 
and comorbidity information to identify five clusters in a sample 
of 5983 patients with moderate–severe OSA [21]. Subsequently, 
they examined the relationship between OSA clusters and “suc-
cessful CPAP treatment”—a composite endpoint of daily CPAP 
usage ≥4 hr and either a decrease in ESS of at least four points 
if baseline ESS≥11 or an increase in 36-item Short Form Health 
Survey (SF-36) energy/vitality of at least seven points. Based on 
this endpoint, clusters with the most severe OSA were more 
likely to respond to treatment. Similarly, a recent study using 
data from the European Sleep Apnea Database (ESADA) com-
pared demographics, comorbidities, and PAP adherence among 
four a priori–defined clusters based on the combination of 
excessive daytime sleepiness (EDS), nocturnal sleep problems 
(insomnia), both, or neither in patients with AHI ≥ 5 events per 
hour [22]. In addition to confirming a higher rate of cardiovas-
cular disease among patients with OSA with insomnia symp-
toms, as in our disturbed sleep cluster, results suggest that PAP 
adherence may be lower among patients exhibiting insomnia-
like symptoms and higher among those with EDS [22]; a similar 
result has also been seen in Iceland [50].
Altogether, these studies support the utility of recognizing 
underlying OSA clusters in clinical care. Alternative treatment 
options may be required to achieve the desired efficacy within 
certain clusters, as well as cluster-specific definitions of suc-
cessful treatment that more accurately capture an individual 
patient’s disease characteristics and response to therapy.
Strengths and limitations
Our present study represents an important follow-up to the origi-
nal cluster analysis performed in ISAC. Replication of the original 
result and extending the definitions of these clusters to a more 
ethnically diverse sample are crucial steps towards understand-
ing OSA heterogeneity and, thus, important strengths of this 
study. Other strengths include the participation of multiple inves-
tigators from internationally recognized sleep centers and the 
application of common questionnaires and phenotyping meth-
odology across a diverse group of patients. The SAGIC sample rep-
resents a unique opportunity to understand ethnic similarities 
and dissimilarities with respect to the complex disease of OSA.
There are also limitations to the present study. The focus 
on patients with moderate–severe OSA means that the clusters 
found here may not be generalizable to patients with milder 
OSA. Similarly, reflecting the established demographic risk fac-
tors for OSA, the cohort was generally middle-aged, moderately 
obese, and predominantly male. Additional studies within pop-
ulations that are younger (or, alternatively, of advanced age), less 
obese, or with more females would help further understand the 
generalizability of these clusters. There were differences in aver-
age AHI severity between the participants from Iceland and the 
sample from outside of Iceland; this likely reflects the impact 
of predominantly home-based sleep tests in Iceland compared 
with polysomnography at other sites [51]. Given the design of 
SAGIC, patients were recruited from clinical sleep centers and 
thus may not be representative of the general population, where 
there is likely a high prevalence of undiagnosed OSA. In fact, a 
recent population study in Iceland [32] observed a high preva-
lence of moderate–severe OSA, but found that participants 
identified in the general population generally had minimal 
symptoms. Thus, the less symptomatic clusters described here 
may be more prevalent in the general population. Similar to the 
ISAC study, we defined most symptoms as present if they were 
reported to occur at least 1–2 times per week. Although alterna-
tive definitions (e.g. at least three times per week) would alter 
the prevalence of characterized symptoms, sensitivity analyses 
in ISAC suggested subtypes are robust to this definition [17]. 
Similarly, our analyses utilized LCA, a specific clustering method 
that leverages categorical responses to determine clusters; other 
clustering methods could be considered in future analyses. Our 
study did not include all possible symptoms and comorbidities 
(e.g., depression, cognitive impairment, and obstructive lung 
disease) that may occur in patients with OSA. As discussed 
throughout this article, inclusion of these additional factors 
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may lead to novel clusters. Nevertheless, results here support 
the existence of OSA clusters that are valid across ethnicities 
and international borders. New approaches need to be adopted 
to identify different clusters when they present and to develop 
personalized strategies to therapy.
Conclusion
This study both replicates and extends previously identified clini-
cal presentation clusters of disturbed sleep, minimally sympto-
matic, and excessively sleepy OSA patients. Both the symptom 
characteristics and prevalence of these clusters were replicated in 
an independent sample of similar Icelandic ancestry as the origi-
nal interrogation. Moreover, these clusters were shown to exist in 
a more ethnically diverse international sleep center population, 
albeit at a different prevalence. In extending the original result to 
five clusters in this ethnically diverse sample, we identified two 
more specific OSA clusters with upper airway symptoms domi-
nant and sleepiness dominant, in addition to clusters similar to 
the three found in ISAC. Although these new clusters could pro-
vide some added clinical benefit by recognizing primary symp-
toms more easily, our results ultimately suggest that, regardless 
of the number of clusters, insomnia-related complaints, exces-
sive sleepiness, and a lack of these symptoms are important char-
acteristics distinguishing patients with OSA with similar disease 
severity. Differences in cluster prevalence and associations with 
ethnicity or demographics among the subtypes suggest that, as 
has been seen for OSA etiology, symptom reporting and perceived 
consequences of OSA may differ across ethnic groups. Future 
studies should explore targeted interventions implied by these 
clusters, as well as examine the utility of incorporating biological 
or genetic factors when defining OSA clusters. It will be essen-
tial to develop clinical tools that efficiently classify a new OSA 
patient presenting at the sleep clinic into the appropriate clus-
ter. Ultimately, this understanding should facilitate personalized 
medicine approaches in OSA patients.
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